Bristol-Myers Squibb Sells French Consumer Health Unit UPSA To Taisho For $1.6bn
Executive Summary
Bristol-Myers Squibb has joined the big pharma trend of divesting non-core assets to focus on high-margin prescription drugs by agreeing to sell over-the-counter drugs business UPSA for $1.6bn to Japanese healthcare firm Taisho Pharmaceutical.
You may also be interested in...
Biopharma Quarterly Dealmaking Statistics, Q4 2018
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.
Deal Watch: Gilead Signs Two Deals In Two Days To Increase R&D Emphasis
As it moves away from virology, Gilead’s signs fibrosis collaboration with Scholar Rock. Novartis seeks to acquire CMDO that manufactures Kymriah, while Intrexon regains control of CAR-T program partnered with Merck KGAA. More deals from over the holiday period…
Asia Deal Watch: Innovent Picks Up Asian Rights To Three Clinical Cancer Candidates From Incyte
Incyte gets $40m up front and can earn up to $351.5m in milestones pegged to a Phase III JAK1 inhibitor and a pair of Phase II candidates. Shionogi obtains Asian rights to an allosteric inhibitor for cognitive disorders from Tetra.